Mergers & acquisitions
The Boston-based company merged with Capstar Special Purpose Acquisition Corp. and will begin trading on the New York Stock Exchange under the ticker symbol “GLS.”
BioNTech indicates the acquisition will add production capacity in support of U.S. clinical trials.
Medtech company HeartFlow is heading to the New York Stock Exchange through a merger with special purpose acquisition company, Longview Acquisition Corp. II.
Prenetics, which is a diagnostics and genetics testing company, will merge with Artisan Acquisition, a SPAC company backed by Adrian Cheng, chief executive officer of Hong Kong’s New World Development.
No specific financial details were disclosed other than to say the $1 billion figure was linked to various development and commercial milestones.
Novo Nordisk will take over Prothena’s wholly-owned subsidiary and gain full global intellectual property rights and other related rights for the latter’s ATTR amyloidosis business and pipeline.
Philip Morris will acquire Vectura to gain access to its inhaled drug formulas to bolster its Beyond Nicotine strategy.
Upon completion of the merger, Parexel will be owned by EQT IX Fund and the private equity business within Goldman Sachs Asset Management.
The deal was originally inked in 2005, where U.S.-based Chiron Corp. made payments to Genentech, a Roche company.
The decision to exercise the option was based on an interim analysis of the ongoing Phase I trial of TNB-383B.
PRESS RELEASES